8/17/2011. FY 2010 President s Budget Request Total NIH Budget Authority $31.0 Billion

Transcription

1 NIH OD NCI NEI NHLBI NHGRI NIA NIAAA NIAID NIAMS NIBIB NICHD NIDCD NIDCR NIDDK NIDA NIEHS NIGMS NIMH NINDS NINR NLM CIT CSR FIC NCCAM NCMHD NCRR FY 2010 President s Budget Request Total NIH Budget Authority $31.0 Billion National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) FY 2010 Budget Distribution by Mechanism 1

2 New Investigators on R01 Awards as a Percentage of Competing Investigators FY 2004 FY 2005 FY 2006 IC New - T1 IC New - T1 IC New - T1 1 FIC 75.0% 1 FIC 66.7% 1 FIC 70.0% 2 NINR 26.1% 2 NINR 35.3% 2 NCCAM 50.0% 3 NIDCD 24.4% 3 NLM 30.0% 3 NLM 42.9% 4 NICHD 23.9% 4 NIDCD 23.4% 4 NINR 33.3% 5 NHGRI 22.0% 5 NCI 23.1% 5 NIBIB 28.1% 6 NIA 21.8% 6 NIBIB 22.7% 6 NIAAA 22.1% 7 NCCAM 21.4% 7 NIAMS 21.1% 7 NINDS 20.8% 8 NIEHS 21.0% 8 NICHD 19.5% 8 NHLBI 20.7% 9 NCI 20.7% 9 NIMH 19.5% 9 NCI 20.4% 10 NIMH 20.1% 10 NHGRI 19.4% 10 NCRR 20.0% 11 NCRR 20.0% 11 NIH 18.0% 11 NIDA 19.7% 12 NIAID 18.7% 12 NHLBI 17.3% 12 NIGMS 19.0% 13 NIH 18.6% 13 NIGMS 16.9% 13 NIDCD 18.6% 14 NIDCR 18.2% 14 NINDS 16.4% 14 NIH 18.5% 15 NHLBI 18.1% 15 NEI 16.1% 15 NICHD 17.9% 16 NINDS 17.9% 16 NIEHS 15.9% 16 NIAID 17.9% 17 NIGMS 17.5% 17 NIAID 15.8% 17 NHGRI 16.7% 18 NIDDK 16.9% 18 NIDCR 15.7% 18 NIMH 15.8% 19 NIAAA 16.4% 19 NIDA 15.3% 19 NEI 14.9% 20 NIAMS 16.2% 20 NIDDK 14.9% 20 NIDDK 13.7% 21 NIBIB 14.9% 21 NIA 14.5% 21 NIAMS 13.7% 22 NLM 14.3% 22 NIAAA 11.2% 22 NIA 13.3% 23 NEI 12.5% 23 NCRR 8.3% 23 NIDCR 13.3% 24 NIDA 11.6% 24 NCCAM 7.7% 24 NIEHS 10.5% Mistaken Idea that Reviewer s Make Funding Decisions at NIH NIH reviewers, who judge the excellence of the science of a proposal, will not ultimately determine its funding fate. NIH Institutes and Centers have the final say as to what gets funded NIH is fond of saying Reviewers judge; Institutes fund. What does this mean? GET TO KNOW NIH and TALK TO PROGRAM STAFF! PA vs. RFA 2

3 Parent PA Code (s) Number Organization Date (SF424 Only) Date R01* Research Project Grant (Parent R01) PA NIH 12/17/ /05/ /08/2013 R03* NIH Small Research Grant Program (Parent R03) PA NIH 12/17/ /16/ /08/2013 Institute-Specific PA Title: Human Pluripotent Stem Cell (hpsc) Research Using Non-Embryonic Sources (R01) Announcement Type New Update: The following update relating to this announcement has been issued: December 4, 2009 This FOA has been updated to reflect the new requirements from NIH s Enhancing Peer Review Initiative. The new requirements are effective for submissions intended for due dates January 25, 2010 and beyond. If submitting an application intended for a due date of January 25, 2010 and beyond, follow the guidance below and be sure to use the Adobe-Forms-B version of the applicaion formd and instructions. If applying for a due date before January 25, 2010, follow the guidance in the archived version of this FOA and be sure to use the Adobe-Forms-A version of the application forms and instructions. NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov ( using the SF424 Research and Related (R&R) forms and the (R&R) Application Guide. APPLICATION MAY NOT BE SUBMITTED IN PAPER FORMAT. This FOA must be read in conjunction with the application guidelines with this announcement in Grants.gov/ApplyforGrants (hereafter called Grants.gov/Apply). A registration process is necessary before submission and applicants are highly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV. Requests for Applications Title: Integrated Preclinical/Clinical Program for HIV Topical Microbicides (U19) Announcement Type This is a re-issuance with modifications, as a Request for Applications, of a previous Program Announcement, PAR , last released on June 9, 2003 Update: The following update relating to this announcement has been issued: November 28, 2008 This RFA has been reissued as (RFA-AI ). March 2, 2008 This RFA has been reissued as (RFA-AI ) Request For Applications (RFA) Number: RFA-AI Catalog of Federal Domestic Assistance Number(s) 3

4 Regarding Grants (FK notes) Strategy for Assistant Professors (first grant) Assistant Prof ~3 to 5 year clock New PIs submit grants after year 2 or 3. Bad idea!! If you have little publication or track record, you lack independence! Need to increase publication record and preferably last author. It is important to publish quickly (2-3 papers a year) at early stages (Impact factor 3-5)! NIH Career Development Programs ( NUMBER OF RESEARCH CAREER AWARDS BY DISTRIBUTION OF AWARDS Number of Awards Fiscal Year *Activities sorted by number of awards in FY Count includes non-competing continuations. Competing applications for K04, K11, K14, K15, K16, K17 and K20 were discontinued in FY K99, KL1 and KL2 are new activities as of FY CD 12 NIH Extramural Data Book last update May 2008 Data provided by the Division of Information Services, Reporting Branch 4

5 Career Applications, Awards Success Rates 2009 Apps Awards Success K % K % K % K99/R % Sample Roster Index Roster Information CSR AA1 AA2 AA3 AA4 AIDS AITC Committee Name Center for Scientific Review CSR STANDING COMMTTEES Biomedical Research Review Subcommittee Epidemiology, Prevention and Behavior Research Review Subcommittee Clinical, Treatment and Health Services Research Review Subcommittee Neuroscience Review Subcommittee NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Acquired Immunodeficiency Syndrome Research Review Committee NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES Allergy, Immunology and Transplantation Research Committee CSR Study Section Roster Index Navigate the CSR website to view categories of study sections of interest CSR SBIR/STTR Study Sections Small business innovation research and small business technology transfer application CSR Fellowship Study Section Rosters Includes review of fellowship grant applications (F30, F31, F32, F33) CSR Regular Standing Study Section Rosters R01,R03, R21, AREA, and K applications amongst others All other CSR Study Sections 5

6 Sample Roster Index for Regular Standing Study Sections and Continuing SEPs Study Section Study Section Description SRO Acronym ACE AIDS Clinical Studies and Epidemiology Study HILARY SIGMON Section ACTS Arthritis, Connective Tissue and Skin Study AFTAB ANSARI Section ADDT AIDS Discovery and Development of SHIV PRASAD Therapeutics Study Section AED Anterior Eye Disease Study Section JERRY TAYLOR AICS Atherosclerosis and Inflammation of the LARRY PINKUS Cardiovascular System Study Section AIP AIDS Immunology and Pathogenesis Study MARY WALKER Section CSR Study Section ADDT Click on the meeting dates to view the meeting rosters Lists all members present (permanent/temporary) Provides total scope of expertise Most current and two prior rosters provided when available Current rosters posted 30 days before meeting date View Roster link on the left shows the membership roster of chartered members only Study Section Membership SRO Meeting Rosters Acronym Roster ADDT View Roster SHIV PRASAD 11/19/2010 7/8/2010 3/19/2010 (Roster) (Roster) (Roster) Specific Areas Covered by ADDT Development of targeted screens for discovery of new HIV agents Isolation and characterization of natural products as therapeutics/preventives for opportunistic infections Preclinical development of therapies for HIV/AIDS, AIDS-associated opportunistic infections, and cancers [including toxicology and pharmacology] Design and development of vectors for targeted delivery to cells and tissues, and for in vivo use Preclinical evaluation of gene-based therapies [e.g. ribozymes, trans-dominant inhibitors, antisense and si-rna] Mechanisms of drug resistance Assay development for molecular-based measures of resistance, therapeutic efficacy, and effects of therapy on immune parameters Chemistry, pharmacology, and biochemistry of target compounds for HIV and AIDS-associated opportunistic infections Studies of drug-drug interactions ADDT has the following shared interest within the AARR IRG: Studies dealing with mechanism of action, regulation, and means of interaction of viral genes and/or gene products with host factors are reviewed by AMCB, whereas ADT reviews application that use this information for assays and screen in therapeutics discovery. ADDT shares interest with AOIC in studies of AIDS-associated opportunistic-infections. ADDT reviews targeted screening, natural products isolation, and characterization and drug development, after anti-microbial/viral activity has been established, whereas AOIC covers the microbiology of the opportunistic infections, especially their pathogenesis. 6

7 NIH Basics: Helpful Web Sites All About NIH Grants Tutorial NIH Grants Information /Career%20Development%20Grants.pdf NIH Grant Writing Tips Tips for New NIH Applicants Applications and Forms Application Receipt Dates 7